{"product_id":"mckesson-bcg-matrix","title":"McKesson Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMcKesson’s BCG Matrix preview highlights where its core business lines may sit—potential Cash Cows in distribution, Stars in specialty pharma services, and areas that warrant scrutiny—yet it’s only the surface. Purchase the full BCG Matrix for quadrant-by-quadrant placements, data-driven recommendations, and strategic moves tailored to McKesson’s market dynamics. Get instant access to a ready-to-use Word report plus an Excel summary to present, prioritize investments, and act with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology and Multispecialty Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncology and Multispecialty is McKesson’s primary growth engine, with management projecting revenue growth of 29–33% for fiscal 2026, driven by higher-margin oncology services.\u003c\/p\u003e\n\u003cp\u003eThe 2024 acquisition of 70% of Core Ventures plus integration of Florida Cancer Specialists and PRISM Vision expanded McKesson’s community-oncology share, adding an estimated $1.2–1.5 billion in annualized revenue.\u003c\/p\u003e\n\u003cp\u003eSegment requires heavy capital for acquisitions and specialized cold-chain distribution, but delivers superior adjusted EBITDA margins (~9–12%) versus traditional wholesale (~3–5%).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharma Services and RxCelerator\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a Star in McKesson’s BCG matrix, Biopharma Services and RxCelerator leads the fast-growing specialty drug market, capturing an estimated 28% share of specialty-commercialization services in 2024 and supporting ~1.2 million patients through access programs.\u003c\/p\u003e\n\u003cp\u003eThe unit cuts prescription abandonment by ~22% and lowers patient OOP (out‑of‑pocket) costs by an average $430 per script, creating sticky revenue with pharma partners.\u003c\/p\u003e\n\u003cp\u003eOngoing 2024–25 investments—about $180m in digital platforms and integrations with 45 manufacturers—drive growth but consume cash as it scales tech and services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGLP-1 Medication Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe GLP-1 medication surge—driven by obesity and diabetes treatments—helped McKesson add over one-third of its recent revenue growth, with specialty pharmacy sales up roughly 35% in 2024 and GLP-1 volumes cited as a main driver.\u003c\/p\u003e\n\u003cp\u003eMcKesson controls a dominant distribution share—estimates show it handles ~30–40% of U.S. specialty drug flows via retail and health-system channels—giving scale for these high-cost therapies.\u003c\/p\u003e\n\u003cp\u003eDespite lower per-unit margins, GLP-1s’ rapid volume growth and market forecasts (CAGR ~20%+ to 2028) make them a BCG Matrix Star: high growth, high relative share, and strategically critical to future top-line expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmaceutical Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMcKesson’s specialty pharmaceutical distribution is a BCG Star: it leads the market as complex biologics now drive roughly 50% of global drug spend and specialty revenues grew ~8% in 2024, sustaining high growth and share.\u003c\/p\u003e\n\u003cp\u003eThe unit’s dominance rests on cold-chain logistics and complex handling that create strong entry barriers; McKesson reports ~65% market share in US specialty distribution as of 2024.\u003c\/p\u003e\n\u003cp\u003eTo keep pace, McKesson invests in validated facilities and automated temperature-monitoring systems, spending hundreds of millions annually—about $300M+ capex in 2023–2024—to scale capacity for rising biologic demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket position: Star—high growth, high share\u003c\/li\u003e\n\u003cli\u003eBiologics: ~50% of drug spend (2024)\u003c\/li\u003e\n\u003cli\u003eMarket share: ~65% US specialty (2024)\u003c\/li\u003e\n\u003cli\u003eCapex: ~$300M+ invested 2023–24 in facilities\/systems\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription Technology Solutions (RxTS)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrescription Technology Solutions (RxTS) is a McKesson star: targeting double-digit CAGR by linking biopharma, providers, and patients via digital networks and analytics, driving scale in a $19 billion medication access and adherence market.\u003c\/p\u003e\n\u003cp\u003eRxTS holds a strong competitive position with operating profit forecast up to 18% in fiscal 2026, fueled by recurring SaaS fees and platform-driven referrals; revenue growth is data-led and high-margin.\u003c\/p\u003e\n\u003cp\u003eHigh demand for data-driven healthcare means continued R\u0026amp;D and tech spend—typical for a star—supporting durable growth but requiring capex to sustain competitive advantage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size: $19B medication access\/adherence\u003c\/li\u003e\n\u003cli\u003eTarget: double-digit CAGR\u003c\/li\u003e\n\u003cli\u003eOp profit: up to 18% in FY2026\u003c\/li\u003e\n\u003cli\u003eModel: SaaS + platform referrals\u003c\/li\u003e\n\u003cli\u003eNeed: ongoing R\u0026amp;D\/tech investment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMcKesson’s Stars: Oncology, Specialty Distribution, Biopharma \u0026amp; RxTS Powering FY26 Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: McKesson’s Oncology\/Multispecialty, Biopharma Services\/RxCelerator, Specialty Distribution, and RxTS are high-growth, high-share units—driving FY2026 revenue growth (Oncology +29–33%), ~65% US specialty distribution share (2024), ~28% specialty commercialization share (2024), and RxTS targeting double-digit CAGR with op profit up to 18% (FY2026).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003e2024–26 KPIs\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e+29–33% rev growth FY2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty Dist.\u003c\/td\u003e\n\u003ctd\u003e~65% US share (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharma\u003c\/td\u003e\n\u003ctd\u003e~28% market share (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRxTS\u003c\/td\u003e\n\u003ctd\u003eop profit ≤18% FY2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix for McKesson: strategic guidance on Stars, Cash Cows, Question Marks, Dogs with investment, hold, or divest recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page McKesson BCG Matrix placing each business unit in a quadrant for rapid strategic clarity\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNorth American Pharmaceutical Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNorth American Pharmaceutical Distribution is McKesson’s largest segment, producing over 90% of 2024 revenue—about $250 billion of total company sales—in a mature oligopoly with AmerisourceBergen and Cardinal Health.\u003c\/p\u003e\n\u003cp\u003eIt generates massive, steady cash flow used to fund oncology and biopharma services expansion; McKesson reported $6.8 billion operating cash flow in FY2024 to support capex and M\u0026amp;A.\u003c\/p\u003e\n\u003cp\u003eWith market growth near 1–2% annually, strategy focuses on efficiency, automation, and milking the high-volume, low-margin network via distribution scale and cost per script reductions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail National Account Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLong-standing national account contracts with retailers like CVS Health, which represented about 23.9% of McKesson’s consolidated revenue in FY2024, produce predictable cash flows that classify this segment as a Cash Cow.\u003c\/p\u003e\n\u003cp\u003eThese partnerships deliver high market share but low growth, needing limited promotional spend to sustain margins, so free cash is steady.\u003c\/p\u003e\n\u003cp\u003eMcKesson uses the cash to service debt—net debt was roughly $9.6 billion at year-end 2024—and to fund consistent dividends to shareholders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenerics and Private-Label Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMcKesson’s generics and private-label medical supplies sit in a mature market with stable demand and ~15–18% U.S. market share in core channels, leveraging scale to secure supplier rebates and lower COGS.\u003c\/p\u003e\n\u003cp\u003eHigher gross margins—around 9–11% vs branded distribution’s 4–6% in 2024—reflect bargaining power and efficient logistics, driving stronger EBITDA per SKU.\u003c\/p\u003e\n\u003cp\u003eLow incremental capex needs let this unit free up cash; in FY2024 it contributed an estimated $1.1–1.3 billion in operating cash flow that McKesson can redeploy into its 2025 restructuring and tech investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth System and Institutional Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSupplying hospitals and large health systems is McKesson’s foundational, high-stickiness cash cow—U.S. distribution market share near 30% and long-term contracts limit churn.\u003c\/p\u003e\n\u003cp\u003eThis mature segment posts low-single-digit revenue growth (~2–4% annually as of 2025) from an aging population and higher prescription volumes, delivering predictable margins.\u003c\/p\u003e\n\u003cp\u003eExisting infrastructure converts most revenue into free cash flow—McKesson generated $8.7B free cash flow in fiscal 2024—funding investments into higher-growth Stars.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market share ~30%\u003c\/li\u003e\n\u003cli\u003eGrowth ~2–4% (2025)\u003c\/li\u003e\n\u003cli\u003eFY24 free cash flow $8.7B\u003c\/li\u003e\n\u003cli\u003eLong-term contracts = low churn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Management Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMcKesson’s pharmacy management technology generates steady recurring revenue from software licenses, maintenance, and hardware, with retention rates above 90% in its installed base; in 2024 McKesson reported ~40% of Medical-Surgical segment gross margin driven by recurring services, underscoring cash flow reliability.\u003c\/p\u003e\n\u003cp\u003eThe core pharmacy software market is mature and low-growth, but McKesson’s large installed base—serving ~20,000 pharmacies and long-term care sites—keeps these products as a Cash Cow funding digital health R\u0026amp;D and acquisitions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring revenue: licenses, maintenance, hardware\u003c\/li\u003e\n\u003cli\u003eCustomer retention: \u0026gt;90%\u003c\/li\u003e\n\u003cli\u003eInstalled base: ~20,000 sites\u003c\/li\u003e\n\u003cli\u003eRole: funds digital health investments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMcKesson: Cash‑generating pharmacy titan—$8.7B FCF, ~30% US share, \u0026gt;90% software retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMcKesson’s North American distribution and pharmacy tech are Cash Cows: ~30% market share, 2–4% growth (2025), FY2024 free cash flow $8.7B, operating cash flow $6.8B, net debt ~$9.6B; long-term contracts (CVS ~23.9% revenue) and \u0026gt;90% software retention fund M\u0026amp;A, dividends, and tech investments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY24 free cash flow\u003c\/td\u003e\n\u003ctd\u003e$8.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY24 operating cash flow\u003c\/td\u003e\n\u003ctd\u003e$6.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (YE2024)\u003c\/td\u003e\n\u003ctd\u003e$9.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket share (US distribution)\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth (2025)\u003c\/td\u003e\n\u003ctd\u003e2–4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCVS revenue share (FY24)\u003c\/td\u003e\n\u003ctd\u003e23.9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy sites (installed)\u003c\/td\u003e\n\u003ctd\u003e~20,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware retention\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eMcKesson BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact McKesson BCG Matrix report you will receive after purchase—no watermarks, no demo content, just a fully formatted, analysis-ready document designed for strategic clarity and professional presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748545507705,"sku":"mckesson-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/mckesson-bcg-matrix.png?v=1772209416","url":"https:\/\/growthsharematrix.com\/products\/mckesson-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}